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Abstract
The early detection of atherosclerotic disease is vital to the effective prevention and management of life-threatening cardiovas-
cular events such as myocardial infarctions and cerebrovascular accidents. Given the potential for positron emission tomography
(PET) to visualize atherosclerosis earlier in the disease process than anatomic imaging modalities such as computed tomography
(CT), this application of PET imaging has been the focus of intense scientific inquiry. Although 18F-FDG has historically been the
most widely studied PET radiotracer in this domain, there is a growing body of evidence that 18F-NaF holds significant diagnostic
and prognostic value as well. In this article, we review the existing literature on the application of 18F-FDG and 18F-NaF as PET
probes in atherosclerosis and present the findings of original animal and human studies that have examined how well 18F-NaF
uptake correlates with vascular calcification and cardiovascular risk.
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Introduction
As amajor contributor to many life-threatening and debilitating
diseases, atherosclerosis is among the foremost causes of mor-
bidity and mortality throughout the world [1]. It is directly
responsible for the majority of ischemic cardiovascular and
cerebrovascular events, which claim the lives of 7.0 and 2.8
million people every year, respectively [2]. Moreover, it is an
underlying cause of peripheral vascular disease, which affects
202 million individuals globally [3]. The economic toll of ath-
erosclerosis is equally staggering; in the US alone, heart disease
and stroke are estimated to cost over $240 billion annually [4].
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Risk factors such as hypertension, hypercholesterolemia, dia-
betes, and smoking put individuals at risk of developing athero-
sclerosis by damaging the vascular endothelium and setting off a
cascade of proinflammatory responses as shown schematically in
Fig. 1 [7]. In the initial stages, vascular permeability is increased,
allowing for infiltration and retention of low-density lipoprotein
cholesterol (LDL), and peripheral monocytes are drawn into the
intimal layer and transformed into macrophages. As these LDLs
are oxidized, they are ingested by macrophages, forming foam
cells that subsequently undergo apoptosis and necrosis. The
resulting breakdown products, including oxidized lipids and cel-
lular debris, make up a highly thrombogenic lipid core covered
by a collagen-rich fibrous cap. These plaques can expand with
further accumulation of lipids and eventually rupture with the
weakening of the fibrous cap, causing life-threatening events
such as myocardial infarction and ischemic stroke.
The inflammatory process of plaque formation triggers an-
other chain of events that gives rise to the calcification of the
vascular wall [8]. In the early phases of this progression, cy-
tokines released by inflammatory cells, such as TNF-α and
IGF-1, induce the formation of lipid-laden plaques as well as
the osteogenic transformation of the surrounding vascular
smoothmuscle cells. These changes create a positive feedback
loop that causes further osteogenic differentiation and gives
rise to microcalcifications that coalesce and ultimately per-
vade the atherosclerotic plaque, intimal layer, and medial layer
[9]. Calcifications under 50 μm in size are generally consid-
ered microcalcifications, which are a marker of cell death and
inflammation and carry an increased risk of plaque rupture
and associated complications. Macrocalcifications, on the oth-
er hand, measure greater than 50 μm and may actually impart
plaque stability [10]. Clinically, plaques at this stage of calci-
fication may be irreversible. A review of randomized con-
trolled clinical trials has not shown that therapeutic interven-
tions (e.g. statins) slow the progression of coronary artery
calcification [5]. Further, high-intensity statin therapy has
been found to increase calcification [11]. The mechanism pro-
posed was substantial delipidation and increased vascular
smooth muscle calcification.
Given the enormous human and economic cost of athero-
sclerosis and its downstream effects, early and effective detec-
tion—particularly of plaques vulnerable to rupture—is para-
mount. Assessment of Framingham risk factors such as dys-
lipidemia, hypertension, and diabetes can identify those at risk
of developing atherosclerotic disease, but cannot shed light on
the extent or vulnerability of existing plaques. Clinical evalu-
ations performed in symptomatic patients, such as the ankle-
brachial index and cardiac stress tests, offer some insight into
the presence of intraluminal stenosis, but the degree of steno-
sis alone has not been shown to be predictive of plaque rupture
[7, 12]. The most reliable means of risk stratification therefore
remains radiologic examination, which can visualize not only
luminal stenosis but also plaque morphology. The plaque
composition most strongly associated with rupture includes
a thin fibrous cap, a lipid-rich necrotic core, neovasculariza-
tion, intraplaque hemorrhage, and microcalcifications [13].
Fig. 1 Progression from healthy arteries to complicated lesions. FDG and
NaF uptake have long been known to precede vascular calcification
evident on CT and intravascular ultrasonography (IVUS) [5, 6]. The
paradigm shift is the stronger predictive power of NaF uptake and the
occurrence of active calcification measured by 18F-NaF uptake in early
coronary fatty streaks and preatheroma (CAC coronary artery calcium)
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The anatomic imaging modalities that have historically
been used in the assessment of atherosclerosis have tended to
focus on noncompositional parameters. Conventional ultraso-
nography and angiography techniques can be used to examine
the extent of luminal stenosis, while cardiac CT can be used to
produce calcium scores to quantify the calcification of the cor-
onary vessels. However, other modalities, including multide-
tector CT coronary angiography, MRI, intravascular ultraso-
nography (IVUS), and optical coherence tomography, have
begun to be implemented with the specific aim of determining
plaque composition [13, 14]. By virtue of being anatomic in
nature, these modalities are best suited to illustrating late-stage
structural changes or calcifications within the vessel walls, and
lack the sensitivity and chemical specificity for early detection.
Unlike their anatomic counterparts, molecular imaging mo-
dalities are capable of detecting microscopic processes such as
inflammation and microcalcification. These chemical composi-
tion changes occur early in the disease process and precede the
aforementioned morphologic developments (Fig. 1). Foremost
among these molecular techniques is positron emission tomog-
raphy (PET) using the radiotracer 18F-fluorodeoxyglucose (18F-
FDG), a radiolabeled glucose analog that serves as a marker of
metabolic activity and, by extension, inflammation. By contrast,
18F-sodium fluoride (18F-NaF) is a specific marker of bone min-
eralization that has traditionally been used in diagnosing meta-
static bone cancer, but has recently been applied to vascular
calcification. The aim of this reviewwas to examine the available
literature on 18F-NaF PET as a diagnostic and prognostic tool in
comparison with the more established method of 18F-FDG PET.
18F-FDG in the detection of atherosclerosis
18F-FDG, the most widely utilized PET radiotracer by far, was
among the first molecular probes used for the assessment of
atherosclerosis and is perhaps the best studied to date. Early
studies showed a correlation between 18F-FDG activity within
the vasculature and atherosclerotic and cardiovascular risk fac-
tors, promoting its utility as a diagnostic agent [15–18]. Further
investigation revealed more direct evidence of a link between
18F-FDG uptake and atherosclerotic disease. Studies in patients
with a history of cerebrovascular accidents showed elevated
18F-FDG activity in 58–85% of carotid lesions [19, 20].
Tawakol et al. performed PET scans in patients with severe
carotid stenosis prior to endarterectomy, and found a significant
correlation between 18F-FDG uptake in carotid plaques and
macrophage staining on corresponding pathology specimens
[21]. In a similar study, Rudd et al. used autoradiography to
demonstrate that 18F-FDG-avid lesions in patients with symp-
tomatic carotid stenosis line up with macrophage-rich areas of
plaque in endarterectomy specimens [22]. The authors also
found that 18F-FDG uptake was 27% higher in symptomatic
carotid lesions than in contralateral asymptomatic lesions [22].
Other studies have provided some evidence that 18F-FDG
PET imaging can be used to evaluate plaque vulnerability and
the risk of associated ischemic events. Figueroa et al. found that
plaques with high-risk morphologic characteristics on CT and
histopathology have significantly higher 18F-FDG avidity [23].
Patients with increased arterial 18F-FDG uptake have been
found to be significantly more likely to go on to suffer an ische-
mic cardiovascular event [24] or a cerebrovascular event [25].
The role of 18F-FDG PET in monitoring the effects of var-
ious treatments for atherosclerotic disease has also been inves-
tigated. In a study of 43 patients undergoing 18F-FDG PET for
cancer screening, Tahara et al. randomized subjects to undergo
either pharmacologic intervention with simvastatin or dietary
modification alone, and found that only the treatment group
showed a significant decrease in plaque SUV [26]. Ogawa et
al. randomized hyperlipidemic rabbits to receive either the an-
tioxidant probucol or no intervention at all, and found that the
SUV of the aorta decreased significantly in the former group
and increased gradually in the latter group [27]. They also
found that the animals in the treatment arm demonstrated sig-
nificantly lower macrophage infiltration of the aorta on histol-
ogy [27]. In a similar study using a rabbit model, Worthley et
al. found that aortic 18F-FDG uptake significantly increased in
animals in which an atherogenic diet was continued and de-
creased in those in which a normal diet was restored [28].
Although these findings strongly suggest that 18F-FDG ac-
tivity is associated with the atherosclerotic disease process,
this link is distinct from the structural changes captured by
anatomic imaging modalities. Across multiple studies, 18F-
FDG avidity has been shown to be highly discordant with
CT findings. In a study of 85 patients, Tatsumi et al. found
no correlation between 18F-FDG uptake and CTcalcium score
[29]. Similarly, studies comparing sites of hypermetabolism
on PET with those of hyperdensity on CT have shown vastly
incongruent results. Ben-Haim et al. and Dunphy et al., in
studies including 122 and 78 patients, found agreement in
only 7% and 2% of cases, respectively [30, 31]. Patients with
high 18F-FDG uptakewere generally found to be younger than
those with extensive calcification, suggesting that high 18F-
FDG uptake represents an earlier stage in the disease process.
It has been postulated that uptake of 18F-FDG is representative
of the inflammatory activity of activatedmacrophages infiltrating
the fibrous cap, which predisposes plaques to rupture [32].
However, this has been a point of contention in the literature. A
study in eight patients with carotid atherosclerosis showed heavy
macrophage infiltration in plaques with 18F-FDG avidity [22],
while another study in 21 patients with peripheral artery disease
showed no significant correlation between 18F-FDG activity and
levels of CD68, a measure of macrophage content [33].
Perhaps the most significant limitation of 18F-FDG as a
probe for atherosclerosis is its intense uptake by myocardial
tissue. The spillover from this physiologic activity obscures
pathologic inflammation from atherosclerotic plaques, greatly
2192 Eur J Nucl Med Mol Imaging (2018) 45:2190–2200
limiting the utility of the modality in assessing the coronary
vasculature. A method of mitigating this limitation is to sup-
press myocardial glucose metabolism by requiring the patient
to fast or consume a high-fat, low-carbohydrate diet prior to
image acquisition [34–36]. Although these protocols are in
clinical use for mediastinal pathologies such as sarcoidosis, they
have not been as widely studied or implemented in coronary
atherosclerosis. As a result, 18F-FDG ismost commonly used to
evaluate atherosclerosis within the carotid arteries, the aorta,
and its larger offshoots. However, even during delayed imaging
of these structures, the contrast resolution is limited by the
retention of radiotracer in the surrounding tissues, blood pool,
and vessel wall. Another limitation, which applies to 18F-FDG
as well as 18F-NaF, is the spatial resolution of PET; visualiza-
tion of microcalcifications in the millimeter range may be
constrained by the physical limits of the modality [21, 37].
18F-NaF in the detection of atherosclerosis
Although its application to vascular imaging is relatively recent,
18F-NaF has shown considerable promise in allowing the evalu-
ation of patients at risk of atherosclerosis. It differs from 18F-FDG
PETin itsmolecular binding characteristics and, thus, themanner
in which it illustrates disease burden. Whereas 18F-FDG is taken
up by metabolically active cells and is considered a surrogate for
inflammation, 18F-NaF is incorporated into areas of calcium de-
position by exchanging the hydroxyl ions of hydroxyapatite crys-
tals with radiolabeled fluoride to form fluorapatite [38].
Consequently, 18F-NaF PET scans are not affected by the major
limitation of myocardial uptake and can be used to assess the
coronary arteries in addition to the peripheral vasculature. The
uptake of 18F-NaF in bone is orders of magnitude greater than in
the vasculature, and thus it is vital to focus imaging on the vas-
culature to minimize background bone uptake of the tracer.
Several studies have shown that vascular uptake of 18F-
NaF is not only correlated with advancing age, but also with
risk factors for atherosclerotic and cardiovascular disease
[39–43]. This was the earliest evidence that themodality could
be diagnostic for atherosclerosis and spurred a series of con-
firmatory studies. Among these was a prospective trial per-
formed by Joshi et al. in 40 patients undergoing 18F-NaF PET/
CTafter myocardial infarction [44]. Uptake was highest in the
culprit plaque in 93% of patients. Moreover, plaques with high
18F-NaF activity were significantly more likely to demonstrate
high-risk morphologic features—namely, positive remodel-
ing, microcalcification, and necrosis of the lipid core—on ul-
trasonography. It is plausible that the observed increase in NaF
uptake in culprit lesions is attributable to the permeability of
ruptured plaques, but there is no evidence of this to our knowl-
edge. The fact that patients were imaged after myocardial
infarction limits the ability of the study to inform risk assess-
ment in patients prior to plaque rupture. Longitudinal NaF
studies in the same subjects in the absence and presence of
myocardial infarction/stenting are needed.
Recent research effort has sought to validate 18F-NaF PET
in comparison with existing diagnostic tools. More specifical-
ly, the distribution of vascular uptake has been compared with
that of calcified plaques visualized on CT. In a retrospective
study in 61 patients, Li et al. found a significant correlation
between 18F-NaF uptake and calcification on CT in the coro-
nary arteries, but not in the aorta [45]. Derlin et al. performed a
similar study in 75 patients, most of whom exhibited multiple
sites of 18F-NaF uptake and arterial calcification on CT.
Notably, the vast majority (88%) of sites with 18F-NaF activity
on PET were colocalized with calcifications seen on CT, but
far fewer sites of calcification (12%) showed elevated 18F-
NaF uptake [46]. These results suggest that 18F-NaF activity
can indicate the presence of microcalcifications before they
are large enough to be visualized on CT. Moreover, the lack
of 18F-NaF uptake at sites of macrocalcification discernible by
anatomic imaging techniques suggests that these plaques are
no longer undergoing active calcium deposition.
The clinical application of 18F-NaF PET in atherosclerosis
requires validation in large prospective studies, as much of the
data that has appeared in the literature thus far has been derived
from single center retrospective studies with limited sample
sizes. Additional prospective studies are especially vital to de-
termining the modality’s prognostic value, which hinges on the
ability to identify plaques at risk of rupture. The specificity of
18F-NaF for this application is also worthy of investigation;
although not as intense asmyocardial uptake of 18F-FDG, back-
ground uptake of 18F-NaF may be sufficient in some patients to
preclude differentiation between vulnerable and stable plaques.
18F-NaF as a marker of cardiovascular
microcalcification in animal studies
The potential of 18F-NaF PET for the early detection of ath-
erosclerosis has been illustrated most vividly in animal stud-
ies. McKenney-Drake et al. and Salavati et al. used the
Ossabaw miniature swine model of metabolic syndrome
(MetS) to demonstrate that 18F-NaF uptake in the coronary
arteries precedes the emergence of macroscopic calcification
on IVUS and CT scans [47–49].
To investigate NaF as a marker of early coronary artery
calcium (CAC, microcalcification), a study was conducted in
this preclinical model. The study included 13 lean (control)
swine and 11 swine with MetS and early coronary artery dis-
ease (CAD). When fed a high-calorie atherogenic diet and
forced to live a sedentary lifestyle, the Ossabaw swine devel-
oped progressive CAD from the stages of clinically insignifi-
cant fatty streaks through necrotic, flow-limiting lesions with
macrocalcifications detectable on IVUS [50, 51]. CAC was
measured using invasive methods (IVUS, histopathology) to
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compare with 18F-NaF uptake in the coronary arteries to test
the hypothesis that 18F-NaF PET imaging can detect CAC
earlier than the current gold standard noninvasive CT scanning
[47–49]. Details related to the characterization of the Ossabaw
swine have been previously reported [50].
These studies relied on the Alavi-Carlsen global molec-
ular calcium score (GMCS), a quantification system
pioneered in an earlier 18F-NaF PET study by Beheshti et
al. [43]. A measure of total cardiac uptake, the GMCS is
calculated by summing the product of SUV and volume of
the region of interest (ROI) on every slice within the borders
of the heart [42, 43, 52] (Fig. 2a). All pigs, lean and MetS,
showed no evidence of CAC on CTwith an Agatston calci-
um score of 0. Simultaneous PET imaging showed that 18F-
NaF uptake in the heart was almost 2.5-fold higher in MetS
pigs than in lean pigs (GMCS 351 ± 17 vs. 145 ± 26, p <
0.05) [49] (Fig. 2b). Plaque burden was also measured using
IVUS in these two groups of pigs. Images of the proximal
15 mm of the right coronary artery (RCA) showed no ath-
erosclerotic plaque burden in lean pigs (Fig. 3a), in contrast
to a plaque burden indicating the early stage of CAD in
MetS pigs (Fig. 3b). MetS pigs had 100-fold greater plaque
burden than lean pigs (0.2 ± 0% vs. 20 ± 1%, p < 0.05; Fig.
3c). Of the MetS pigs with CAD, two showed evidence of
focal CAC on IVUS (Fig. 3d).
To better represent this early stage of CAD, another
IVUS technique—percent wall coverage (PWC)—was used
as a surrogate for atherosclerosis. The PWC of the proximal
RCAwasmore variable than the percent plaque burden data.
An example of early CAD (i.e., fatty streak, preatheroma,
intimal thickening), with a low percent plaque burden
(about 13%), is shown as concentric wall coverage (100%)
in Fig. 4a. Strong evidence for PWC on IVUS as a quanti-
tative measure of intimal thickening is the correlation be-
tween PWC and Verhoeff–van Gieson histologic staining
(r = 0.93, p < 0.0001). As expected, in MetS pigs PWC
was about fivefold greater than in lean pigs (57 ± 9% vs.
12 ± 3%, p < 0.05; Fig. 4b). Compared to 18F-NaF uptake
in the RCA of each pig, PWC was significantly correlated
with microcalcification activity measured on PET (p < 0.05,
r = 0.61; Fig. 4c). These findings are reported by
McKenney-Drake et al. [49] as separate values for the left
anterior descending artery and the RCA.
Biochemical assessment revealed no significant differ-
ence in the calcium content of the left ventricle (Fig. 5a)
between lean pigs (1.11 ± 0.05 μmol/g) and MetS pigs
(1.17 ± 0.06 μmol/g, p = 0.24; Fig. 5b). Furthermore, histo-
pathology did not reveal evidence of ventricular calcifica-
tion (Fig. 5c, d). Taken together, these findings suggest that
the measured 18F-NaF uptake did not come from the ven-
tricular tissue of the heart.
This preclinical PET/CT study demonstrated that increased
18F-NaF uptake in coronary arteries is a biomarker for early
CAC in pigs with CAD that lack frank evidence of calcifica-
tion on IVUS and CT imaging. These findings imply that 18F-
NaF binds to microcalcifications too small to be detected
using anatomic/morphologic imaging modalities, an interpre-
tation that is strengthened by histopathology data revealing
sparse calcifications within the proximal region of the coro-
nary artery. The histopathology findings did not significantly
correlate with 18F-NaF uptake in the coronary arteries, sug-
gesting that histologic assessment detects macroaggregates of
hydroxyapatite, but not the microcalcifications visualized on
18F-NaF PET/CT [49]. The findings of this animal study and
others that have used the same preclinical swine model of
CAD [50, 51, 53, 54] hint at a role for 18F-NaF PET/CT in
the early detection of atherosclerosis, but validation is re-
quired in human studies.
18F-NaF as a marker for cardiovascular
microcalcification in human studies
To further investigate the value of 18F-NaF PET/CT in the
clinical evaluation of atherosclerosis, we analyzed 124 hu-
man subjects, including 80 healthy controls and 44 patients
Fig. 2 Coronary artery global
molecular calcification score
(GMCS) and percent injected
dose per gram body weight 18F-
NaF uptake. aA region of interest
was drawn around the heart on
each cardiac CT slice from which
GMCS was calculated. b Pigs
with metabolic syndrome (MetS;
n = 11) had a GMCS almost 2.5-
fold higher than lean pigs (n = 2;
*p < 0.05)
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with chest pain syndromes. These subjects belonged to the
Cardiovascular Molecular Calcification Assessed by 18F-
NaF PET/CT (CAMONA) study in Odense, Denmark. All
subjects underwent a 90-min 18F-NaF PET/CT scan and a
180-min 18F-FDG PET/CTscan under similar conditions. A
whole-vessel analysis in axial sections was then performed
for the three vascular segments of the thoracic aorta, includ-
ing the ascending aorta, aortic arch and descending aorta.
Measures of arterial microcalcification including average
SUVmax, average SUVmean, and Alavi-Carlsen GMCS
were calculated for each vascular segment as well as for
the whole vessel using previously described methods.
Vascular 18F-NaF uptake quantified as average SUVmax,
average SUVmean, and GMCS was significantly higher in
patients than in healthy controls. Of note, age was signifi-
cantly correlated with average SUVmax, average SUVmean
and GMCS in all vascular segments and the whole vessel,
although the correlation coefficients were higher in patients
with chest pain syndromes (Fig. 6). GMCS of the thoracic
aorta was a stronger predictor of 10-year Framingham risk
score (FRS) than average SUVmax and average SUVmean
(adjusted R2 = 0.38, standardized β = 0.58, p < 0.001).
Moreover, GMCS of the thoracic aorta was a borderline
significant predictor of an unfavorable CVD risk profile as
compared to average SUVmax and average SUVmean
(odds ratio = 1.006, 95% CI = 1.000–1.013, p = 0.05). 18F-
FDG uptake in the thoracic aorta quantified as average
SUVmax and average SUVmean was positively correlated
with age; however, the correlation was not significant in the
healthy group.
We also assessed the extent of cardiac microcalcification
in another subset of subjects from the CAMONA study that
included 40 healthy subjects and 38 patients with chest pain
syndromes. To quantify cardiacmicrocalcification, ellipsoid
ROIs were manually drawn around cardiac ventricles by an
experiencedphysician onaxial PET/CTimages starting from
the base to the cardiac apex excluding the aortic valve
(Fig. 7). Alavi-Carlsen GMCS was not correlated with age
in healthy subjects (r = 0.11, p = 0.48), but was positively
correlated with increasing age in patients with cardiovascu-
lar disease risk factors (r = 0.30, p = 0.04). These findings
highly suggest that global assessment of cardiovascular
microcalcification has potential applications for prompt risk
stratification and therapeutic intervention in patients at high
risk of cardiovascular disease. Given the evidence that 18F-
NaF is able to detect arterial calcifications earlier than CT,
this approach holds promise as a clinical alternative to the
conventional CT-based calcium score.
Fig. 3 IVUS images and
quantification of early-stage CAD
(type I, II, and III lesions). a, b, d
Cross-sectional view of a
coronary artery in Ossabaw pigs.
a A lean pig (vascular wall traced
in red). b A pig with metabolic
syndrome and CAD (initial lumen
traced in red, actual lumen traced
in yellow); percent plaque
burden = (initial − actual)/
initial) × 100. c Pigs with
metabolic syndrome (MetS; n =
7) had significantly more
extensive CAD than lean pigs
(n = 2) as shown by plaque
burden quantification in the
proximal 15 mm of the right
coronary artery (p < 0.05). d One
pig showed evidence of focal
calcification (green arrow lesion,
green lines acoustic shadowing).
Distance between blue dots is
1 mm
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Comparing 18F-FDG and 18F-NaF as diagnostic
and prognostic tools for atherosclerosis
Once the value of molecular imaging for evaluating patients at
risk of atherosclerotic disease had been demonstrated, com-
parisons between available PET radiotracers became an area
of scientific inquiry. Although numerous radiotracers have
been investigated for this indication, including 18F-
fluoromethylcholine [55, 56], a biomarker for structural wall
alteration, 18F-FDG and 18F-NaF remain the most widely
studied and compared.
Studies that have correlated 18F-FDG and 18F-NaF activity
with clinical and pathologic measures of disease have consis-
tently found that 18F-NaF is more strongly correlated. In a
prospective study in 119 subjects, Dweck et al. found that,
while 18F-NaF uptake in coronary arteries and the aorta was
significantly correlated with 10-year FRS, 18F-FDG uptake
was not [57]. Likewise, coronary 18F-NaF activity was signif-
icantly associated with increased rates of CAD and angina, as
well as with histories of coronary revascularization and major
adverse cardiac events, but 18F-FDG activity was not. In a
prospective study of 139 subjects (89 healthy volunteers and
Fig. 4 Early stage CAD was quantified as percent wall coverage using
IVUS. a Cross-sectional image of a coronary artery in an Ossabaw pig
with metabolic syndrome with 100% wall coverage (concentric fatty
streak, intimal thickening) and a plaque burden of about 13%, which
would not be clinically significant. b Pigs with metabolic syndrome
(MetS; n = 8) had a percent wall coverage about fivefold greater than lean
pigs (n = 3; *p < 0.05). c RCA intimal wall coverage is significantly
correlated with 18F-NaF uptake (p < 0.05). Distance between blue dots
is 1 mm
Fig. 5 Calcium content of the left ventricle. a Specimen was collected
from the left ventricle away from any conduit artery (yellow box). b There
is no difference in left ventricle calcium content between lean pigs (n = 6)
and MetS pigs (n = 11). c, d Histopathology of the left ventricle: c von
Kossa mineral staining on fast green background (showing mineral as
black sediment ) ) showed no evidence of myocardia l or
microvasculature calcification in either lean pigs or MetS pigs; d
Masson’s trichrome staining shows healthy nonfibrotic myocardium
(arrows microvessels)
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50 patients), Blomberg et al. similarly found that an increased
risk of cardiovascular disease as estimated by FRS was asso-
ciated with vascular calcification metabolism as measured by
18F-NaF, but was not associated with 18F-FDG uptake [42]. In
a prospective study in 40 patients with prior myocardial infarc-
tion, Joshi et al. found that 18F-NaF uptake occurred very reli-
ably in culprit plaques in the coronary arteries and
histologically-confirmed sites of active calcification, macro-
phage infiltration, apoptosis, and necrosis [44]. No such rela-
tionship was observed for 18F-FDG. In both of these studies,
the authors concluded that physiologic uptake of 18F-FDG by
the myocardium obscured pathologic uptake in the coronary
arteries, drastically limiting the ability to evaluate atheroscle-
rotic burden using this radiotracer. Such comparisons were also
extended to other cardiovascular conditions involving calcifi-
cation and inflammation, producing similar results. In a study
in 101 patients with aortic stenosis of varying severity and 20
controls, Dweck et al. found that uptake of both radiotracers
was significantly higher in patients, but that 18F-NaF uptake
was better correlated with the severity of valvular disease [58].
Studies comparing these molecular imaging probes with
radiologic and serologic assessments of arterial calcification
have also shown 18F-NaF to be better correlated. In a study in
45 patients, Derlin et al. found that 18F-NaF had far superior
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Fig. 6 18F-NaF average SUVmean in the aortic arch wall in relation to
age in healthy controls (a) and patients with cardiovascular risk factors
(b). The average SUVmean (mean ± SD) in the aortic arch in healthy
controls and patients were 0.87 ± 0.30 and 1.07 ± 0.37, respectively
(p = 0.002). The Spearman correlation coefficients for the healthy
controls and patients were 0.32 (p = 0.04) and 0.64 (p < 0.001),
respectively
Fig. 7 Transverse images (left CT, middle PET, right PET/CT) of the
heart (green circles) in two clinically normal subjects (a 25 years old, b
61 years old). The global cardiac calcification scores were 12,492.44 in
subject a and 18,424.70 in subject b. Normalizing the values to
background NaF uptake increases the discrepancy between the subjects,
resulting in 2.18 times the uptake in subject b than in subject a.
Corresponding to the sites of NaF uptake in subject b, no structural
calcification is seen on the corresponding CT scan and there is
significant disparity between the PET and CT results. This is not an
uncommon observation in this setting and clearly demonstrates the
basis for assessment of cardiovascular calcification with these two
different imaging modalities. While molecular imaging with NaF
detects the earliest evidence for vascular calcification, evidence for
calcification on CT largely reflects an end-stage disease process and
therefore may be an irreversible pathologic state. Disparity between
these two observations provides evidence for stage of calcification and
has implications for the irreversibility of macrocalcification
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colocalization with CT calcifications than 18F-FDG (77.1%
vs. 14.5%) [59], and also suggested that the specificity of
18F-NaF is superior to that of 18F-FDG, as the target-to-
background uptake ratio of 18F-NaF (2.3) exceeded that of
18F-FDG. Two prospective studies by Dweck et al. confirmed
that 18F-NaF uptake is significantly correlated with CT calci-
um scores, while 18F-FDG uptake is too intense in the myo-
cardium to enable detection of coronary pathology [57, 60].
The more recent of the two studies [60] also compared the
radiotracers with histologic measures of inflammation and
calcification. Levels of CD68, the macrophage-associated in-
flammatory marker, were not associated with uptake of either
agent. However, alkaline phosphatase and osteocalcin, surro-
gates for calcification, were found to be correlated with 18F-
NaF alone.
Increasingly, there is evidence that molecular calcification
may be the initial biologic process for development of athero-
sclerotic plaques in the arteries [61, 62]. This may improve our
ability to detect this serious disorder in its earlier stages since
18F-NaF-based PET imaging is less prone to the complexities
that are associated with PET imaging of this disorder.
Conclusion
In this review, we have outlined evidence in the literature re-
garding the use of the molecular imaging probes 18F-NaF and
18F-FDG in detecting the chemical composition and vulnerabil-
ity of atherosclerotic plaques. Despite possessing distinct bind-
ing properties that interrogate entirely different components of
the disease process, these radiotracers were initially shown to be
associated with many of the same clinical risk factors for ath-
erosclerosis and cardiovascular disease [15–18, 39–41, 43].
Moreover, the uptake of both 18F-FDG and 18F-NaF was found
to be increased not only in vulnerable plaques with high-risk
morphologies, but also in ruptured plaques that cause myocar-
dial infarctions and cerebrovascular accidents [25, 44].
However, the similarities ended when these PET probes
were compared to anatomic imaging modalities, most notably
CT calcium scores. While 18F-NaF correlated well with these
conventional measures of atherosclerotic burden, 18F-FDG
demonstrated no such relationship [29–31, 42, 46]. This ob-
servation speaks to the different mechanisms of action of these
radiotracers. The role of 18F-NaF in illustrating the calcifica-
tion that takes place in atherosclerotic disease is plainly evi-
dent in its correlation with CT calcium scores and
colocalization with CT-detected macrocalcifications and path-
ologically confirmed microcalcifications. Thus, the data sup-
port the use of 18F-NaF PET as the best modality for the early
detection of disease as it has been shown to pick up
microcalcifications before they become visible on CT scans
in humans [46] and even in fatty streaks in swine [36–38]. In
contrast, 18F-FDG is not associated with these markers of
calcification, but is linked to the inflammatory component of
atherosclerosis, which is a critical risk factor for plaque rup-
ture [32]. In addition, as a nonspecific glucose analog, 18F-
FDG has the unique disadvantage of intense myocardial up-
take, which obscures activity in the coronary arteries, and
essentially restricts the applications of 18F-FDG to the periph-
eral vasculature [44, 57]. Largely because of this phenome-
non, head-to-head studies comparing 18F-FDG and 18F-NaF
have consistently shown that the latter is better correlated with
clinical, pathologic, and radiologic measures of disease.
The relative specificity of 18F-NaF PET, as well as its com-
parative advantage in the early detection ofmicrocalcifications
(Fig. 1), position the modality well as a clinical tool for the
diagnosis of atherosclerotic disease. The use of 18F-NaF PET
could allow earlier intervention and improved outcomes, and
studies combining this technique with CT calcium score or
MRI may offer further sensitivity and specificity. A few early
studies have already begun to demonstrate the utility of hybrid
imaging for this indication [63, 64]. Given the promise and
potential it has shown thus far, it appears that molecular im-
aging can, with continued validation, take hold in the clinical
setting and improve our diagnosis and management of a dis-
ease that underlies some of the most common causes of mor-
bidity and mortality throughout the world.
In two recent editorials, we have discussed current limita-
tions of PET in assessing cardiovascular disorders and the
suboptimal methodologies that are being employed in this
structurally and biologically complicated domain [65, 66]. In
particular, we have emphasized the challenges that are faced in
overcoming image degradation due to cardiac and respiratory
motion. We also have proposed global disease assessment in
the coronary and major arteries to overcome these obstacles
for accurate quantification of molecular abnormalities that are
associated with atherosclerotic plaques.
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